TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from CASI Pharmaceuticals ( (CASI) ) is now available.
On November 14, 2025, CASI Pharmaceuticals announced its third-quarter 2025 business and financial results, highlighting ongoing advancements in its CID-103 clinical program. The company is preparing for a Phase 1 study in the U.S. for renal allograft antibody-mediated rejection (AMR) and is conducting a Phase 1 study for immune thrombocytopenia (ITP). Financially, CASI reported a 60% decrease in revenue to $3.1 million compared to the previous year, primarily due to changes in the distribution agreement for EVOMELA®. The company also faced a net loss increase to $10.9 million and received a Nasdaq delisting determination due to non-compliance with market value requirements, which it is appealing.
The most recent analyst rating on (CASI) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Underperform.
CASI Pharmaceuticals receives a low overall stock score due to significant financial challenges, including declining revenue and high leverage. The technical analysis indicates a bearish trend, and the valuation is unattractive with a negative P/E ratio. These factors collectively contribute to the low score.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody aimed at treating organ transplant rejection and autoimmune diseases. The company holds exclusive global rights to CID-103 and is actively pursuing its development in both the U.S. and China.
Average Trading Volume: 227,975
Technical Sentiment Signal: Strong Sell
Current Market Cap: $22.46M
For an in-depth examination of CASI stock, go to TipRanks’ Overview page.